Form 4: Kiniksa Pharmaceuticals Executive John F. Paolini Reports Share Transactions
SEC Form 4 Filing
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, reports the vesting of restricted share units and subsequent share disposals to cover tax obligations.
Summary
- On March 16, 2025, John F. Paolini, the Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, had 1,725 Restricted Share Units (RSUs) vest.
- These RSUs converted into Class A Ordinary Shares.
- Following the vesting, Paolini disposed of 507 Class A Ordinary Shares at a price of $22.61 to satisfy tax obligations.
- After these transactions, Paolini directly owns 53,256 Class A Ordinary Shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to executive compensation, with no inherent positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and does not necessarily indicate a significant event for Kiniksa Pharmaceuticals.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/16/2021 | Date of grant for the Restricted Share Units (RSUs), which vest over a four-year period. |
| 03/16/2025 | Date of the reported transactions: vesting of RSUs and disposal of shares. |
| 03/19/2025 | Date of signature for the Form 4 filing. |
Keywords
Kiniksa Pharmaceuticals, KNSA, Form 4, Beneficial Ownership, John F. Paolini, Restricted Share Units, Class A Ordinary Shares, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.